All Practice Exams

100+ Free BCTXP Practice Questions

Pass your Board Certified Transplant Pharmacist (Solid Organ Transplantation Pharmacy) exam on the first try — instant access, no signup required.

✓ No registration✓ No credit card✓ No hidden fees✓ Start practicing immediately
100+ Questions
100% Free
1 / 100
Question 1
Score: 0/0

Thymoglobulin (rabbit ATG) works primarily by:

A
B
C
D
to track
2026 Statistics

Key Facts: BCTXP Exam

150

Total Items

125 scored + 25 unscored

30%

Largest Domain Weight

Induction & Maintenance Immunosuppression

2018

BPS Specialty Established

Solid Organ Transplantation Pharmacy

$600

Initial Exam Fee

BPS

500

Passing Scaled Score

Range 200-800

BPS

Specialty Body

Solid Organ Transplantation Pharmacy

The BCTXP (Board Certified Transplant Pharmacist) exam is administered by BPS for the Solid Organ Transplantation Pharmacy specialty. The exam consists of 150 items (125 scored + 25 unscored) with a passing scaled score of 500 (range 200-800). The fee is $600 initial / $300 retake. Induction and Maintenance Immunosuppression is the largest domain at 30%, followed by Rejection/Complications and Post-Transplant Infection (each 20%). Mastery of CYP3A4 drug interactions, TDM target troughs, and Banff rejection criteria is essential.

Sample BCTXP Practice Questions

Try these sample questions to test your BCTXP exam readiness. Each question includes a detailed explanation. Start the interactive quiz above for the full 100+ question experience with AI tutoring.

1Which class of human leukocyte antigens (HLA) includes the A, B, and C loci?
A.Class I
B.Class II
C.Class III
D.Class IV
Explanation: HLA Class I antigens include the A, B, and C loci and are expressed on virtually all nucleated cells. They present intracellular (endogenous) peptides to CD8+ cytotoxic T cells.
2Which HLA class II locus is considered the most important for kidney transplant matching?
A.HLA-DP
B.HLA-DQ
C.HLA-DR
D.HLA-DM
Explanation: HLA-DR is the most important class II locus for kidney transplant matching. The standard 6-antigen match considers HLA-A, HLA-B, and HLA-DR (2 alleles each).
3Signal 1 in T-cell activation involves:
A.Binding of CD28 to CD80/CD86
B.TCR recognition of antigen-MHC complex
C.IL-2 binding to the IL-2 receptor
D.Calcineurin dephosphorylation of NFAT
Explanation: Signal 1 is the T-cell receptor (TCR) recognition of an antigen presented by MHC on an antigen-presenting cell. This initiates the calcium-calcineurin-NFAT pathway, which is the target of calcineurin inhibitors.
4Which rejection type is mediated by preformed antibodies and typically occurs within minutes to hours after transplantation?
A.Hyperacute rejection
B.Acute cellular rejection
C.Chronic rejection
D.Subclinical rejection
Explanation: Hyperacute rejection is mediated by preformed donor-specific antibodies (DSA) against ABO or HLA antigens. It occurs within minutes to hours of reperfusion and is now rare due to crossmatch testing.
5The Banff classification is used to grade rejection in which organ?
A.Heart
B.Lung
C.Kidney
D.Liver
Explanation: The Banff classification is the internationally accepted standard for grading kidney allograft rejection on biopsy. It categorizes T-cell mediated rejection (I, II, III) and antibody-mediated rejection.
6C4d staining on biopsy is a key marker for which type of rejection?
A.T-cell mediated rejection
B.Antibody-mediated rejection (AMR)
C.Hyperacute rejection
D.Chronic allograft nephropathy
Explanation: C4d is a complement degradation product that deposits in peritubular capillaries when antibodies activate complement. Positive C4d staining supports a diagnosis of antibody-mediated rejection (AMR).
7Thymoglobulin (rabbit ATG) works primarily by:
A.Blocking IL-2 receptor on T cells
B.Depleting T-lymphocytes
C.Inhibiting calcineurin
D.Blocking CD28 costimulation
Explanation: Rabbit antithymocyte globulin (rATG, Thymoglobulin) is a polyclonal antibody that depletes T-lymphocytes via complement-mediated lysis and apoptosis. It is used for induction and treatment of steroid-resistant rejection.
8Basiliximab (Simulect) is typically dosed as:
A.20 mg IV day 0 and day 4
B.1.5 mg/kg IV daily for 5 days
C.30 mg IV once weekly
D.0.3 mg/kg subcutaneously every 2 weeks
Explanation: Basiliximab is administered as 20 mg IV on day 0 (within 2 hours before transplant) and repeated on day 4 post-transplant. It is a chimeric monoclonal antibody against CD25 (IL-2 receptor alpha chain).
9Which of the following is the primary mechanism of action of tacrolimus?
A.Inhibition of mTOR
B.Inhibition of calcineurin via FKBP-12 binding
C.Inhibition of inosine monophosphate dehydrogenase (IMPDH)
D.Blockade of the IL-2 receptor
Explanation: Tacrolimus binds to FKBP-12, and this complex inhibits calcineurin. This prevents dephosphorylation of NFAT and blocks transcription of IL-2 and other cytokines, inhibiting T-cell activation.
10Which enzyme system is primarily responsible for tacrolimus metabolism?
A.CYP2D6
B.CYP3A4/5
C.UGT1A1
D.CYP2C9
Explanation: Tacrolimus is extensively metabolized by CYP3A4 and CYP3A5. It is also a P-glycoprotein substrate. CYP3A5 expressers (carriers of CYP3A5*1) require higher tacrolimus doses to achieve target troughs.

About the BCTXP Exam

BPS specialty certification for pharmacists practicing in solid organ transplantation. Established in 2018, the BCTXP validates expertise across recipient evaluation and donor selection (HLA, ABO, crossmatch), induction and maintenance immunosuppression (calcineurin inhibitors, antimetabolites, mTOR inhibitors, corticosteroids) with therapeutic drug monitoring, recognition and treatment of acute cellular and antibody-mediated rejection, post-transplant infection prophylaxis (CMV, PJP, antifungal), and long-term comorbidity management (NODAT, CV risk, malignancy surveillance). NOTE: This credential is for Solid Organ Transplant — NOT Toxicology (which is not a current BPS specialty).

Questions

150 scored questions

Time Limit

Per BPS scheduling

Passing Score

Scaled 500 (200-800)

Exam Fee

$600 initial / $300 retake (BPS)

BCTXP Exam Content Outline

15%

Pre-Transplant Evaluation and Optimization

Recipient evaluation, HLA/ABO/crossmatch, waitlist, candidate optimization

30%

Induction and Maintenance Immunosuppression

Induction agents, maintenance regimens, TDM, CYP3A4 interactions

20%

Rejection and Complications

ACR and AMR diagnosis/treatment, chronic allograft dysfunction, CNI nephrotoxicity

20%

Post-Transplant Infection and Prophylaxis

CMV, PJP, antifungal prophylaxis, BK virus, vaccinations

15%

Long-Term Care and Comorbidities

NODAT, CV risk, malignancy surveillance, bone health, adherence

How to Pass the BCTXP Exam

What You Need to Know

  • Passing score: Scaled 500 (200-800)
  • Exam length: 150 questions
  • Time limit: Per BPS scheduling
  • Exam fee: $600 initial / $300 retake

Keys to Passing

  • Complete 500+ practice questions
  • Score 80%+ consistently before scheduling
  • Focus on highest-weighted sections
  • Use our AI tutor for tough concepts

BCTXP Study Tips from Top Performers

1Memorize TDM target troughs by time post-transplant: tacrolimus 8-12 ng/mL early, 5-10 ng/mL at 6-12 months, 4-8 ng/mL maintenance. Cyclosporine C0 100-300 ng/mL or C2 monitoring (1.5-2 hours post-dose, more accurate). Sirolimus 5-15 ng/mL
2Know CYP3A4 inhibitors that DRAMATICALLY increase tacrolimus/cyclosporine: voriconazole (often 50-75% dose reduction needed), posaconazole, clarithromycin, diltiazem (sometimes used INTENTIONALLY for cost savings on cyclosporine)
3Understand standard prophylaxis: CMV — valganciclovir 900 mg PO daily × 3-6 months for D+/R-; PJP — TMP-SMX SS daily or DS 3×/wk for 6-12 months (lifelong for lung); fungal — fluconazole or echinocandin × 1-3 months
4Master Banff rejection grading: ACR Borderline → 1A (interstitial + tubulitis t1) → 1B (t2) → IIA (mild intimal arteritis v1) → IIB (severe v2) → III (transmural arteritis v3 or fibrinoid necrosis)
5Know post-transplant diabetes (NODAT) risk factors: tacrolimus > cyclosporine, steroids, age >40, BMI >30, family history, hepatitis C; preferred agents: GLP-1 agonists, SGLT2 inhibitors (with monitoring for euglycemic DKA + UTI)

Frequently Asked Questions

What does BCTXP actually stand for?

BCTXP = Board Certified Transplant Pharmacist (Solid Organ Transplantation Pharmacy). It was established as a BPS specialty in 2018. BCTXP is sometimes confused with Toxicology — but Toxicology is NOT a current BPS specialty. The credential is exclusively for solid organ transplant pharmacy practice (kidney, liver, heart, lung, pancreas, intestine).

What is the most heavily weighted BCTXP domain?

Induction and Maintenance Immunosuppression carries the largest weight at 30%. This domain covers induction agents (basiliximab, ATG/thymoglobulin, alemtuzumab), maintenance regimens with calcineurin inhibitors (tacrolimus, cyclosporine), antimetabolites (mycophenolate, azathioprine), mTOR inhibitors (sirolimus, everolimus), and corticosteroids — including TDM target troughs and the extensive CYP3A4 drug-drug interactions that affect tacrolimus and cyclosporine.

What CYP3A4 interactions should I know cold?

Tacrolimus and cyclosporine are CYP3A4 substrates. Major inhibitors that increase levels (often dramatically): azoles (especially voriconazole and posaconazole), macrolides (clarithromycin, erythromycin), diltiazem and verapamil, grapefruit juice, ritonavir/cobicistat. Major inducers that decrease levels: rifampin, rifabutin, phenytoin, carbamazepine, phenobarbital, St. John's wort. Always adjust CNI doses and monitor troughs when starting or stopping these.

What's the difference between ACR and AMR?

Acute Cellular Rejection (ACR) is T-cell mediated, diagnosed on biopsy via Banff criteria, treated with high-dose steroid pulse and/or thymoglobulin (rATG) for steroid-resistant cases. Antibody-Mediated Rejection (AMR) is humoral (donor-specific antibodies), diagnosed by C4d staining + DSAs, treated with plasmapheresis + IVIG ± rituximab ± bortezomib ± eculizumab. Mixed rejection requires combined therapy.

How should I study for the BCTXP exam?

Plan 80-120 hours over 10-14 weeks. Focus 30-40% of time on Induction and Maintenance Immunosuppression. Master TDM target troughs (tacrolimus 5-15 ng/mL depending on time post-transplant; cyclosporine C0 100-300 ng/mL or C2 monitoring), CYP3A4 interactions, Banff rejection criteria, CMV/PJP/antifungal prophylaxis durations, and the unique pharmacology of each maintenance class.